Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
British Journal of Cancer|February 16, 2013
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trialN C Tebbutt, M M Parry, D Zannino, et al.
Gynecologic Oncology|April 29, 2006
Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First StudyC B Steer, K Chrystal, K A Cheong, et al.
British Journal of Cancer|January 31, 2013
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinomaM Peeters, A H Strickland, M Lichinitser, et al.
British Journal of Cancer|December 18, 2008
A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancerM Michael, T Price, S Y Ngan, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 6, 2013
Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignanciesG S Patel, K Jain, R Kumar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2012
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancerM M Eatock, N C Tebbutt, C L Bampton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2011
Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabN C Tebbutt, F Murphy, D Zannino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancerM Peeters, T J Price, A Cervantes, et al.
Pageof 2